Clinical Trial: A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

U.S., Jan. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07357727) titled 'A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)' on Jan. 15.

Brief Summary: The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.

Study Start Date: April 15, 2026

Study Type: INTERVENTIONAL

Condition: Primary Myelofibrosis (PMF) Post-polycythemia Vera Myelofibrosis (...